Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis

被引:204
作者
Forrester, E
Chytil, A
Bierie, B
Aakre, M
Gorska, AE
Sharif-Afshar, AR
Muller, WJ
Moses, HL
机构
[1] Vanderbilt Univ, Dept Canc Biol, Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Med, Ingram Canc Ctr, Nashville, TN 37232 USA
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
[4] McGill Univ, Dept Biochem, Montreal, PQ, Canada
关键词
D O I
10.1158/0008-5472.CAN-04-3272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transforming growth factor-beta (TGF-beta) isoforms are growth factors that function physiologically to regulate development, cellular proliferation, and immune responses. The role of TGF-beta signaling in mammary tumorigenesis is complex, as TGF-beta has been reported to function as both a tumor suppressor and tumor promoter. To elucidate the role of TGF-beta signaling in mammary gland development, tumorigenesis, and metastasis, the gene encoding type II TGF-beta receptor, Tgfbr2, was conditionally deleted in the mammary epithelium (Tgfbr2(MGKO)). Loss of Tgfbr2 in the mammary epithelium results in lobular-alveolar hyperplasia in the developing mammary gland and increased apoptosis. Tgfbr2(MGKO) mice were mated to the mouse mammary tumor virus-polyornavirus middle T antigen (PyVmT) transgenic mouse model of metastatic breast cancer. Loss of Tgfbr2 in the context of PyVmT expression results in a shortened median tumor latency and an increased formation of pulmonary metastases. Thus, our studies support a tumor-suppressive role for epithelial TGF-beta signaling in mammary gland turnorigenesis and show that pulmonary metastases can occur and are even enhanced in the absence of TGF-beta signaling in the carcinoma cells.
引用
收藏
页码:2296 / 2302
页数:7
相关论文
共 30 条
  • [1] TGF-β signaling in cancer -: a double-edged sword
    Akhurst, RJ
    Derynck, R
    [J]. TRENDS IN CELL BIOLOGY, 2001, 11 (11) : S44 - S51
  • [2] Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis
    Andrechek, ER
    Hardy, WR
    Siegel, PM
    Rudnicki, MA
    Cardiff, RD
    Muller, WJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3444 - 3449
  • [3] Transforming growth factor β receptor type II inactivation promotes the establishment and progression of colon cancer
    Biswas, S
    Chytil, A
    Washington, K
    Romero-Gallo, J
    Gorska, AE
    Wirth, PS
    Gautam, S
    Moses, HL
    Grady, WM
    [J]. CANCER RESEARCH, 2004, 64 (14) : 4687 - 4692
  • [4] Böttinger EP, 1997, CANCER RES, V57, P5564
  • [5] Conditional inactivation of the TGF-β type II receptor using Cre:Lox
    Chytil, A
    Magnuson, MA
    Wright, CVE
    Moses, HL
    [J]. GENESIS, 2002, 32 (02) : 73 - 75
  • [6] Transforming growth factor-β and breast cancer -: Tumor promoting effects of transforming growth factor-β
    Dumont, N
    Arteaga, CL
    [J]. BREAST CANCER RESEARCH, 2000, 2 (02): : 125 - 132
  • [7] Glick AB, 1996, CANCER RES, V56, P3645
  • [8] Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia
    Gobbi, H
    Dupont, WD
    Simpson, JF
    Plummer, WD
    Schuyler, PA
    Olson, SJ
    Arteaga, CL
    Page, DL
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (24) : 2096 - 2101
  • [9] Gobbi H, 2000, HISTOPATHOLOGY, V36, P168
  • [10] Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
    Gorelik, L
    Flavell, RA
    [J]. NATURE MEDICINE, 2001, 7 (10) : 1118 - 1122